TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Overactive bladder with more than 3 episodes of urgency of urge incontinence per day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Indomethacin Capsules to Treat Pain Following Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female between 18 and 65 years of age~* For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control~* Has undergone primary, unilateral, first metatarsal bunionectomy with no additional collateral procedures~* Patient must be willing to stay at the study site ≥ 72 hours~Exclusion Criteria:~* Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs~* Patient has a current disease or history of a disease that will impact the study or the patient's well-being~* Patient has used or intends to use any of the medications that are prohibited by the protocol~* Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test~* Patient has taken another investigational drug within 30 days prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Indomethacin 40 mg TID (Type: EXPERIMENTAL): None
- Indomethacin 40 mg BID (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Indomethacin 20 mg TID (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a Body Mass Index (BMI) between 20 and 27 kg/m2 (inclusive) and a body weight not less than 50 kg~* Be healthy on the basis of physical examination including medical history, vital signs, 12-lead ECG, and all other screening lab tests performed at Screening and Admission~* Agree (if men) to use a double barrier method of birth control (e.g., condom for them and use of spermacide with diaphragm, hormonal contraceptives or intrauterine devices by female partner) during the study and for three months following the last dose of study medication, and to not donate sperm during the study and for 3 months after receiving the last dose of study medication~* Willing/able to adhere to the prohibitions and restrictions specified in this protocol~* Must have signed an informed consent form.~Exclusion Criteria:~* Have a history of, or currently active, illness or medical condition or disorder that the Investigator considers to be clinically significant~* Has been a smoker or tobacco user within the past 6 months~* Have a history of recent major surgery (within 6 months of study start)~* Tested positive for serology: hepatitis B surface antigen (HBsAg), hepatitis C antibodies (anti-HCV) or human immunodeficiency virus (HIV) antibodies~* Fasting plasma glucose \> 110 mg/dL~* Have a history of alcohol or drug abuse within 2 years prior to Screening or a positive test for alcohol and/or drugs of abuse (including but not limited to barbiturates, opiates, cocaine, cannabinoids, amphetamines,MDMA (Ecstasy) and benzodiazepines) at Screening

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 001 (Type: EXPERIMENTAL): no intervention Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
- 002 (Type: EXPERIMENTAL): Canagliflozin/Placebo Placebo/Canagliflozin Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion criteria:~1. Signed and dated ICF (Informed Consent Form)~2. Male or female on diet and exercise regime and on stable background metformin \> or equal to 1500 mg or maximun dose according to local label~3. HBA1c (Glicoslated Hemoglobin) \> or equal to 8% and \< or equal to 10.5 % at Visit 1~4. HbA1c \> or equal to 7 and \< or equal to 10.5 at Visit 4~5. Age \> or equal to 18 years~6. BMI (Body Mass Index) \< or equal to 45~Exclusion criteria:~1. Uncontrolled hyperglycemia during open label period and placebo add on run-in period~2. Use of any other antidiabetic~3. Renal function below 60 ml/min/1.73 m2~4. Antiobesity drugs or aggresive diets~5. Gastorintestinal surgeries~6. Current systemic steroids or uncontrolled endocrine disorders other than Diabetes Type 2~7. Acute coronary syndrome and stroke within 3 months of informed consent~8. Known allergies to DPP-IV (Dypeptidil Peptidase IV) or SGLT-2 (Sodium Glucose Transporter 2) inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin 10 mg dose (Type: EXPERIMENTAL): Empagliflozin open label treatment period
- Placebo add on 10 mg dose (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
- Empagliflozin/Linagliptin 25/5 mg Dose (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 25/5 mg Dose FDC active
- Empagliflozin/Linagliptin 10/5 mg Dose. (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
- Empagliflozin/Linagliptin 10/5 mg Dose (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 10/5 mg Dose FDC active
- Empagliflozin 25 mg dose (Type: EXPERIMENTAL): Empagliflozin open label treatment period
- Empagliflozin/Linagliptin 25/5 mg Dose. (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
- Placebo add on 25 mg dose (Type: EXPERIMENTAL): Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Side Effects of 4 Times Bone Marrow Mono Nuclear Transplantation in Patients With Ischemic Lower Limb

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemic lower limb based on TASK guide line~* Rutherford score:2,3~* ABI\<0.6~* Absolute ankle pressure \< 60 mmHg~* Both gender~* Age:20-62years~Exclusion Criteria:~* EF\<30%~* Cr\>2~* HbA1c\>8%~* Bone marrow disorders:leukemia~* Cognitive disorders~* Infections~* MI with ST elevation during last month~* Malignancy~* Immunologic or rheumatologic disorders

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 62 Years
- Healthy Volunteers: f

Study Arms:
- 4times injection (Type: EXPERIMENTAL): the patients with ischemic lower limb ulcer who underwent 4times stem cell injection.
- one injection (Type: EXPERIMENTAL): Patients with peripheral artery disease underwent cell transplantation just one time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)~* Post-bronchodilator forced expiratory volume at one second~  /forced vital capacity (FEV1/FVC) level less than 70%~* Ten or more pack-years of smoking~* Willing to make return visits to the study clinic and accept telephone contact~* Last pneumococcal vaccination occured at least 5 years prior to study entry~Exclusion Criteria:~* Asthma~* Sensitivity to pneumococcal vaccine~* Known bleeding disorder, or requires long-term anticoagulation therapy~* Presence of chronic disease that may impair pneumococcal vaccine response~* Acute illness requiring antibiotics in the month prior to study entry~* Medical condition that makes survival for 24 months following study entry unlikely~* Pregnant

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pneumovax (PPSV23) (Type: ACTIVE_COMPARATOR): pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)
- Prevnar (PCV7) (Type: ACTIVE_COMPARATOR): diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: in whom initiation of estrogen therapy has been recommended due to ovarian failure~* Outpatients~* age \>=12 years to 17.99 years old~Exclusion Criteria:~* spontaneous menses~* significant concurrent medical problem including:~* Liver function tests (LFTs) 3 times normal~* clotting disorder~* ongoing cancer treatment

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Vivelle-Dot (Type: ACTIVE_COMPARATOR): 17Beta Estradiol - transdermal
- Premarin (Type: ACTIVE_COMPARATOR): Conjugated estrogens
- Estrace (Type: ACTIVE_COMPARATOR): 17beta Estradiol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Satisfaction, Engagement and Outcomes Among Traditionally Underserved Children Through Cultural Formulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child with elevated behavior problems~* Child is between ages 2-7 years (inclusive)~* Family seeking services at one of the University of Miami PCIT-Community Connect Centers~Exclusion Criteria:~* Parent is actively abusing illegal substances~* Child is younger than 2 years of age~* Child is older than 7 years of age

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Clinical Assessment and CFI (Type: EXPERIMENTAL): CA and CFI families will receive the Cultural Formulation Interview prior to their standard Clinical Assessment during their intake.
- Clinical Assessment Only (Type: ACTIVE_COMPARATOR): CA families will receive a standard Clinical Assessment during intake.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients, \> 50 years of age~* Diagnosed osteoporosis~* Bone mineral density \< minus 2.5 SD or osteoporotic fracture~* At least 3 years after menopause~Exclusion Criteria:~* Impaired renal function~* Contra-indication to Calcium or Vitamin D therapy~* Previous or current treatment with biphosphonates

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age: \>18 years~2. participants older than 18 years with either LAPC according to the American Joint Committee on Cancer (AJCC) criteria or isolated local recurrence with a maximum tumor diameter of 5 cm were considered eligible after pathologic confirmation~3. will receive IRE, gd Tcells~4. life expectancy: more than 3 months~5. ability to understand the study protocol and a willingness to sign a written informed consent document~6. adequate liver and renal function were required~7. intolerant or refused to chemotherapy or to chemotherapy~Exclusion Criteria:~1. patients with other kinds of cancer~2. history of coagulation disorders or anemia~3. heart disease and diabetes~4. history of epilepsy, severe coronary disease, a history of level 3 hypertension，myelosuppression, autoimmune disease~5. a performance status score of \>2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): In this group, the patients will receive IRE surgery to control the local tumor under CT .
- Group B (Type: EXPERIMENTAL): In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and IRE surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes mellitus~* age \>=20 years~* spot urine albumin/creatinine ratio \> 30mg/g in two consecutive measurements~* patients on ACE-inhibitor or ARB as an anti-hypertensive drug~* blood pressure \<= 150/100 mmHg~* HbA1c \<10%~Exclusion Criteria:~* taking insulin pentoxifylline, cilostazol, ketas, viagra in 3 months~* ischemic heart disease, stroke, malignant disease, severe infection in 6 months~* serum creatinine \> 2.0mg/dl~* severe liver disease or AST, ALT \> 3\* ULM~* taking systemic steroid in 1 month~* pregnant or plan to become pregnant during the clinical trial~* lactation

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pentoxifylline (Type: ACTIVE_COMPARATOR): Pentoxifylline 400mg three times a day
- Placebo (Type: PLACEBO_COMPARATOR): placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects with primary hypercholesterolemia or mixed dyslipidemia who are ≥18 and ≤80 years of age at the time of consent~* Plasma Low-density lipoprotein cholesterol (LDL-C) ≥130 milligrams per deciliter (mg/dL) and ≤220 mg/dL and triglyceride (TG) levels of ≤400 mg/dL~Exclusion Criteria:~* Homozygous familial hypercholesterolemia~* Any conditions which may cause secondary dyslipidemia~* Uncontrolled diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- pitavastatin 4 mg once daily (QD) (Type: EXPERIMENTAL): None
- pravastatin 40 mg once daily (QD) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Power Wheelchairs on the Development and Function of Young Children With Severe Physical Disabilities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 14 to 30 months~* Motor impairment that prevents functional independent mobility~* Vision and hearing adequate to use a power mobility device safely.~* Cognitive abilities assessed to be at least equivalent to a 12-month level or alertness and interest in the environment that suggests a trial of power mobility is warranted.

- Gender: ALL
- Minimum Age: 14 Months
- Maximum Age: 30 Months
- Healthy Volunteers: f

Study Arms:
- Power wheelchair (Type: EXPERIMENTAL): None
- Control group (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Diagnosis of diabetes mellitus, type 2~* Patients treated with stable sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 12 weeks prior to screening~* HbA1c \>/=7% and \</=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit~* Fasting plasma glucose \</=240 mg/dL at pre-randomization visit~* Agreement to maintain diet and exercise habits during the study~Exclusion Criteria:~* Patients with Type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months~* Any previous treatment with thiazolidinedione or a dual PPAR agonist~* Any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin)~* Any anti-hyperglycemic medication other than sulfonylurea alone or in combination with metformin within 12 weeks prior to screening~* Symptomatic congestive heart failure classified as New York Heart Association class II-IV at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aleglitazar (Type: EXPERIMENTAL): None
- placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject completed the SP0961 (NCT01118949) study~* Subject is expected to benefit from participation in an open-label extension study with Lacosamide, in the opinion of the investigator~Exclusion Criteria:~* Subject meets the withdrawal criteria for SP0961 (NCT01118949) or is experiencing an ongoing Serious Adverse Event (SAE)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949).~Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete